Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study - Rudin, C M; Pietanza, M C; Bauer, T M (Lancet Oncol, 2016)